Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry

Antiviral targeting of virus envelope proteins is an effective strategy for therapeutic intervention of viral infections. Here, we took a computer-guided approach with the aim of identifying new antivirals against the envelope protein E2 of bovine viral diarrhea virus (BVDV). BVDV is an enveloped vi...

Full description

Bibliographic Details
Main Authors: Pascual, María José, Merwaiss, Fernando, Leal, Emilse Soledad, Quintana, Maria Eugenia, Capozzo, Alejandra Victoria, Cavasotto, Claudio Norberto, Bollini, Mariela, Alvarez, Diego Ezequiel
Format: Artículo
Language:Inglés
Published: Elsevier 2019
Subjects:
Online Access:http://hdl.handle.net/20.500.12123/4480
https://www.sciencedirect.com/science/article/pii/S0166354217305983?via%3Dihub#!
https://doi.org/10.1016/j.antiviral.2017.10.010
_version_ 1855483440908992512
author Pascual, María José
Merwaiss, Fernando
Leal, Emilse Soledad
Quintana, Maria Eugenia
Capozzo, Alejandra Victoria
Cavasotto, Claudio Norberto
Bollini, Mariela
Alvarez, Diego Ezequiel
author_browse Alvarez, Diego Ezequiel
Bollini, Mariela
Capozzo, Alejandra Victoria
Cavasotto, Claudio Norberto
Leal, Emilse Soledad
Merwaiss, Fernando
Pascual, María José
Quintana, Maria Eugenia
author_facet Pascual, María José
Merwaiss, Fernando
Leal, Emilse Soledad
Quintana, Maria Eugenia
Capozzo, Alejandra Victoria
Cavasotto, Claudio Norberto
Bollini, Mariela
Alvarez, Diego Ezequiel
author_sort Pascual, María José
collection INTA Digital
description Antiviral targeting of virus envelope proteins is an effective strategy for therapeutic intervention of viral infections. Here, we took a computer-guided approach with the aim of identifying new antivirals against the envelope protein E2 of bovine viral diarrhea virus (BVDV). BVDV is an enveloped virus with an RNA genome responsible for major economic losses of the cattle industry worldwide. Based on the crystal structure of the envelope protein E2, we defined a binding site at the interface of the two most distal domains from the virus membrane and pursued a hierarchical docking-based virtual screening search to identify small-molecule ligands of E2. Phenyl thiophene carboxamide derivative 12 (PTC12) emerged as a specific inhibitor of BVDV replication from in vitro antiviral activity screening of candidate molecules, displaying an IC50 of 0.30 μM against the reference NADL strain of the virus. Using reverse genetics we constructed a recombinant BVDV expressing GFP that served as a sensitive reporter for the study of the mechanism of action of antiviral compounds. Time of drug addition assays showed that PTC12 inhibited an early step of infection. The mechanism of action was further dissected to find that the compound specifically acted at the internalization step of virus entry. Interestingly, we demonstrated that similar to PTC12, the benzimidazole derivative 03 (BI03) selected in the virtual screen also inhibited internalization of BVDV. Furthermore, docking analysis of PTC12 and BI03 into the binding site revealed common interactions with amino acid residues in E2 suggesting that both compounds could share the same molecular target. In conclusion, starting from a targeted design strategy of antivirals against E2 we identified PTC12 as a potent inhibitor of BVDV entry. The compound can be valuable in the design of antiviral strategies in combination with already well-characterized polymerase inhibitors of BVDV.
format Artículo
id INTA4480
institution Instituto Nacional de Tecnología Agropecuaria (INTA -Argentina)
language Inglés
publishDate 2019
publishDateRange 2019
publishDateSort 2019
publisher Elsevier
publisherStr Elsevier
record_format dspace
spelling INTA44802019-02-21T14:02:16Z Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry Pascual, María José Merwaiss, Fernando Leal, Emilse Soledad Quintana, Maria Eugenia Capozzo, Alejandra Victoria Cavasotto, Claudio Norberto Bollini, Mariela Alvarez, Diego Ezequiel Pestivirus de la Diarrea Bovina Inhibición Viricidas Bovine Diarrhoea Pestivirus Inhibition Antiviral Agents BVDV Protein E2 Proteína E2 Antiviral targeting of virus envelope proteins is an effective strategy for therapeutic intervention of viral infections. Here, we took a computer-guided approach with the aim of identifying new antivirals against the envelope protein E2 of bovine viral diarrhea virus (BVDV). BVDV is an enveloped virus with an RNA genome responsible for major economic losses of the cattle industry worldwide. Based on the crystal structure of the envelope protein E2, we defined a binding site at the interface of the two most distal domains from the virus membrane and pursued a hierarchical docking-based virtual screening search to identify small-molecule ligands of E2. Phenyl thiophene carboxamide derivative 12 (PTC12) emerged as a specific inhibitor of BVDV replication from in vitro antiviral activity screening of candidate molecules, displaying an IC50 of 0.30 μM against the reference NADL strain of the virus. Using reverse genetics we constructed a recombinant BVDV expressing GFP that served as a sensitive reporter for the study of the mechanism of action of antiviral compounds. Time of drug addition assays showed that PTC12 inhibited an early step of infection. The mechanism of action was further dissected to find that the compound specifically acted at the internalization step of virus entry. Interestingly, we demonstrated that similar to PTC12, the benzimidazole derivative 03 (BI03) selected in the virtual screen also inhibited internalization of BVDV. Furthermore, docking analysis of PTC12 and BI03 into the binding site revealed common interactions with amino acid residues in E2 suggesting that both compounds could share the same molecular target. In conclusion, starting from a targeted design strategy of antivirals against E2 we identified PTC12 as a potent inhibitor of BVDV entry. The compound can be valuable in the design of antiviral strategies in combination with already well-characterized polymerase inhibitors of BVDV. Instituto de Virología Fil: Pascual, María José. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Merwaiss, Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Leal, Emilse Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Bionanociencias ; Argentina Fil: Quintana, Maria Eugenia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina Fil: Capozzo, Alejandra Victoria. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología; Argentina. Consejo Nacional de Investigaciones Científicas y Tecnológicas; Argentina Fil: Cavasotto, Claudio Norberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Investigación en Biomedicina de Buenos Aires - Instituto Partner de la Sociedad Max Planck; Argentina Fil: Bollini, Mariela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Centro de Investigaciones en Bionanociencias ; Argentina Dil: Alvarez, Diego Ezequiel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina 2019-02-21T13:54:01Z 2019-02-21T13:54:01Z 2018-01 info:ar-repo/semantics/artículo info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/20.500.12123/4480 https://www.sciencedirect.com/science/article/pii/S0166354217305983?via%3Dihub#! 0166-3542 https://doi.org/10.1016/j.antiviral.2017.10.010 eng info:eu-repo/semantics/restrictedAccess application/pdf Elsevier Antiviral research 149 : 179-190. (January 2018)
spellingShingle Pestivirus de la Diarrea Bovina
Inhibición
Viricidas
Bovine Diarrhoea Pestivirus
Inhibition
Antiviral Agents
BVDV
Protein E2
Proteína E2
Pascual, María José
Merwaiss, Fernando
Leal, Emilse Soledad
Quintana, Maria Eugenia
Capozzo, Alejandra Victoria
Cavasotto, Claudio Norberto
Bollini, Mariela
Alvarez, Diego Ezequiel
Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title_full Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title_fullStr Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title_full_unstemmed Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title_short Structure-based drug design for envelope protein E2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
title_sort structure based drug design for envelope protein e2 uncovers a new class of bovine viral diarrhea inhibitors that block virus entry
topic Pestivirus de la Diarrea Bovina
Inhibición
Viricidas
Bovine Diarrhoea Pestivirus
Inhibition
Antiviral Agents
BVDV
Protein E2
Proteína E2
url http://hdl.handle.net/20.500.12123/4480
https://www.sciencedirect.com/science/article/pii/S0166354217305983?via%3Dihub#!
https://doi.org/10.1016/j.antiviral.2017.10.010
work_keys_str_mv AT pascualmariajose structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT merwaissfernando structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT lealemilsesoledad structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT quintanamariaeugenia structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT capozzoalejandravictoria structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT cavasottoclaudionorberto structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT bollinimariela structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry
AT alvarezdiegoezequiel structurebaseddrugdesignforenvelopeproteine2uncoversanewclassofbovineviraldiarrheainhibitorsthatblockvirusentry